Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study

Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psor...

Descripción completa

Detalles Bibliográficos
Autores principales: MALARA, Giovanna, POLITI, Cristina, TRIFIRÒ, Caterina, VERDUCI, Chiara, D’ARRIGO, Graziella, TESTA, Alessandra, TRIPEPI, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425567/
https://www.ncbi.nlm.nih.gov/pubmed/34043021
http://dx.doi.org/10.2340/00015555-3846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425567/
https://www.ncbi.nlm.nih.gov/pubmed/34043021
http://dx.doi.org/10.2340/00015555-3846

Ejemplares similares